MiniMed™ 780G with Guardian™ 4
Type 1 Diabetes
Key Facts
About Medtronic
Medtronic is a pioneering medical technology company founded in 1949, best known for inventing the first wearable cardiac pacemaker. Its mission to 'alleviate pain, restore health, and extend life' is executed through a diversified portfolio of devices, therapies, and digital solutions across four core operating segments. The company's strategy combines deep clinical expertise, a people-centered approach, and strategic M&A to drive innovation in chronic disease management and personalized care.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |
| Type I Diabetes | Genclis | Discovery |
| Inreda AP® | Inreda Diabetic | Commercial |
| iTOL-101 | iTolerance | Preclinical |